OpenNashEarnings

Biotechnology · Nasdaq: VRTX

Vertex Pharmaceuticals earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 11 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Vertex closed its Crinetics acquisition, adding rare endocrine as a fourth commercial pillar, and now awaits a November 30 FDA decision on povetacicept that could open a fifth in renal.

Vertex closed the Crinetics acquisition on September 1, adding PALSONIFY, a once-daily oral acromegaly drug that holds more than 40% of patients starting or switching therapy. ALYFTREK keeps taking patients from TRIKAFTA in cystic fibrosis. CASGEVY won FDA approval for children as young as 2. JOURNAVX became the most prescribed branded oral pain medicine in the U.S. as prescriptions kept climbing.

Read the Q3 2026 summary →

Quarters

KPI history

Revenue$3.4B+11.8% y/yQ3 2026
Q4 2024: $2.9B (worked out from the annual figure)Q4 ’24$2.9BQ1 2025: $2.8BQ1 ’25$2.8BQ2 2025: $3.0BQ2 ’25$3.0BQ3 2025: $3.1BQ3 ’25$3.1BQ4 2025: $3.2B (worked out from the annual figure)Q4 ’25$3.2BQ1 2026: $3.0BQ1 ’26$3.0BQ2 2026: $3.3BQ2 ’26$3.3BQ3 2026: $3.4BQ3 ’26$3.4B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$2.9B *
Q1 2025$2.8B
Q2 2025$3.0B
Q3 2025$3.1B
Q4 2025$3.2B *
Q1 2026$3.0B
Q2 2026$3.3B
Q3 2026$3.4B
Diluted EPS (GAAP)$2.56−39.0% y/yQ3 2026
Q1 2025: $2.49Q1 ’25$2.49Q2 2025: $3.99Q2 ’25$3.99Q3 2025: $4.20Q3 ’25$4.20Q1 2026: $4.02Q1 ’26$4.02Q2 2026: $4.31Q2 ’26$4.31Q3 2026: $2.56Q3 ’26$2.56
Data
Q1 2025$2.49
Q2 2025$3.99
Q3 2025$4.20
Q1 2026$4.02
Q2 2026$4.31
Q3 2026$2.56

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin20.7%−17.9 pts y/yQ3 2026
Q4 2024: 35.2%Q4 ’2435.2%Q1 2025: 22.7%Q1 ’2522.7%Q2 2025: 38.8%Q2 ’2538.8%Q3 2025: 38.6%Q3 ’2538.6%Q4 2025: 37.8%Q4 ’2537.8%Q1 2026: 38.1%Q1 ’2638.1%Q2 2026: 37.4%Q2 ’2637.4%Q3 2026: 20.7%Q3 ’2620.7%
Data
Q4 202435.2%
Q1 202522.7%
Q2 202538.8%
Q3 202538.6%
Q4 202537.8%
Q1 202638.1%
Q2 202637.4%
Q3 202620.7%
Free cash flow$545.8M−52.1% y/yQ3 2026
Q4 2024: $492.0MQ4 ’24$492.0MQ1 2025: $778.2MQ1 ’25$778.2MQ2 2025: $927.4MQ2 ’25$927.4MQ3 2025: $1.1BQ3 ’25$1.1BQ4 2025: $348.6MQ4 ’25$348.6MQ1 2026: $1.3BQ1 ’26$1.3BQ2 2026: $1.0BQ2 ’26$1.0BQ3 2026: $545.8MQ3 ’26$545.8M
Data
Q4 2024$492.0M
Q1 2025$778.2M
Q2 2025$927.4M
Q3 2025$1.1B
Q4 2025$348.6M
Q1 2026$1.3B
Q2 2026$1.0B
Q3 2026$545.8M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$2.9Bd$2.8B$3.0B$3.1B$3.2Bd$3.0B$3.3B$3.4B
Operating income$1.0Bd$630.1M$1.2B$1.2B$1.2Bd$1.1B$1.2B$712.9M
Operating margin35.2%22.7%38.8%38.6%37.8%38.1%37.4%20.7%
Net income$913.0Md$646.3M$1.0B$1.1B$1.2Bd$1.0B$1.1B$653.6M
Diluted EPS—$2.49$3.99$4.20—$4.02$4.31$2.56
Operating cash flow$584.6Md$818.9M$1.1Bd$1.2Bd$498.0Md$1.4B$1.1Bd$643.1Md
Capital expenditure$92.6Md$40.7M$145.7Md$101.8Md$149.4Md$133.4M$112.2Md$97.3Md
Free cash flow$492.0M$778.2M$927.4M$1.1B$348.6M$1.3B$1.0B$545.8M
R&D expense$998.7Md$979.7M$978.4M$977.7M$973.7Md$961.6M$993.8M$1.3B

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings